BCM
CORT icon

Boxer Capital Management’s Corcept Therapeutics CORT Stock Holding History

Boxer Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
335,500
+85,500
+34% +$5.16M 2.2% 13
2026
Q1 		$10.1M Buy
+250,000
New +$9.35M 1.32% 21

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boxer Capital Management's CORT Position: Q2 2026 in Review

Boxer Capital Management increased its Corcept Therapeutics (CORT) stake by 34% in Q2 2026, buying an estimated $5.16M and bringing the position to 335,500 shares worth $29.2M. The position accounts for 2.2% of the portfolio, ranked #13.

Boxer Capital Management first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Boxer Capital Management held 335,500 shares of Corcept Therapeutics worth $29.2M as of Q2 2026.
  • Boxer Capital Management bought 85,500 Corcept Therapeutics shares in Q2 2026, an estimated $5.16M.
  • Corcept Therapeutics made up 2.2% of Boxer Capital Management's portfolio in Q2 2026, its #13 holding.
  • Boxer Capital Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.